Phase III data on Urocidin in Bladder Cancer published-Bioniche LS

Bioniche Life Sciences has announced that The Journal of Urology has accepted for publication a manuscript entitled: Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression Who Have Failed Treatment with Bacillus Calmette-Gu�rin. It is expected in print April 2015. The data reported in this publication pertains to pivotal Phase III study conducted with MCNA, also known as Urocidin (Mycobacterium phlei cell wall-nucleic acid complex) and includes results of planned statistical analyses at study completion including efficacy rates at 3 and 6 months and 2 years after therapy.

Post-hoc analyses were performed to determine the efficacy of MCNA in subgroups of bacillus Calmette-Gu�rin (BCG)-failure patients and outcomes of treatment such as duration of response, impact on progression and cystectomy rates are also presented. These analyses complement the previous interim study results that appeared in abstract form which were presented at North American and international urology conferences. See: "Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression who Have Failed Treatment with Bacillus Calmette�Gu�rin." Alvaro Morales et al. Journal of Urology Published Online: October 03, 2014 DOI: http://dx.doi.org/10.1016/j.juro.2014.09.109